Liver Neoplasms Clinical Trial
Official title:
Tislelizumab Plus Tyrosine Kinase Inhibitor (TKI) as Adjuvant Therapy Versus Active Surveillance in Patients With HCC at High Risk of Recurrence After Curative Ablation: A Prospective Cohort Study
Background: Ablation is important radical treatment in hepatocellular carcinoma (HCC). However, the 5-year recurrence rate of HCC after ablation is up to 80%. Early and late recurrences are more likely related to tumor size, tumor multiplicity, vascular invasion, higher serum AFP level and disease etiology, etc. Some studies suggested that adjuvant immunotherapy might be associated with decreased recurrence and prolonged RFS. Adjuvant atezolizumab + bevacizumab (IMbrave 050) showed RFS improvement following curative resection or ablation. Currently, there is limited study on immunotherapy combined with TKI as postoperative adjuvant therapy for HCC. This is an open-label, prospective cohort study to compare the efficacy and safety of tislelizumab plus tyrosine kinase inhibitor (TKI) as adjuvant therapy versus active surveillance in HCC patients with high risk of recurrence after curative ablation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03651154 -
Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections
|
N/A | |
| Not yet recruiting |
NCT03592550 -
The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
|
||
| Not yet recruiting |
NCT02521129 -
A New Track Ablation Device for Liver Biopsy: A Feasibility Study
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02168608 -
Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy
|
N/A | |
| Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
| Active, not recruiting |
NCT01177007 -
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
|
Phase 2 | |
| Completed |
NCT00788697 -
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
|
Phase 3 | |
| Recruiting |
NCT01564810 -
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
|
Phase 4 | |
| Completed |
NCT00094003 -
Study of NS-9 in Patients With Liver Metastases
|
Phase 1 | |
| Terminated |
NCT00051532 -
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT00001587 -
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
|
Phase 1 | |
| Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
| Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
| Completed |
NCT03289273 -
Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
|
||
| Terminated |
NCT03349255 -
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
| Recruiting |
NCT03715517 -
Spinal Anesthesia For Enhanced Recovery After Liver Surgery
|
N/A | |
| Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01744054 -
Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
|
Phase 1 | |
| Active, not recruiting |
NCT02969096 -
Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
|
Phase 2 |